Replies

The headline is outright misleading. No, it's worse than that, it's FAKE. The company's press release said "The greatest improvements were seen in patients who hadn't ALREADY mounted a natural response to the infection..." In other words, early. As in before you have developed neutralizing antibodies yourself. Trump likely was diagnosed very early, so is probably a near ideal candidate (pun intended) for this drug.

No, they’ve got it right. I had noted and posted this on another thread earlier today:

White House doctor: Trump received experimental antibody cocktail, remains ‘fatigued’ after COVID-19 diagnosis.
10/2/2020, 4:45:22 PM · 34 of 147
9YearLurker to SpeedyInTexas
This doesn’t sound especially reassuring:

“At the webcast that announced Regeneron’s results, George Yancopoulos, president and co-founder of the company, emphasized how the “target population” for the monoclonal cocktail are SARS-CoV-2 infected people who have “not yet mounted their own immune response” and have exceedingly high levels of the virus. “What we really want to do is turn them into patients who have already started to effectively fight the virus,” Yancopoulos said.”